Skip to main content
Oncotarget logoLink to Oncotarget
. 2021 Oct 12;12(21):2231. doi: 10.18632/oncotarget.28012

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201

Joshua E Allen 1, C Leah B Kline 2, Varun V Prabhu 1, Jessica Wagner 2, Jo Ishizawa 3, Neel Madhukar 4, Avital Lev 2, Marie Baumeister 2, Lanlan Zhou 2, Amriti Lulla 2, Martin Stogniew 1, Lee Schalop 1, Cyril Benes 5,6, Howard L Kaufman 7, Richard S Pottorf 8, B Rao Nallaganchu 8, Gary L Olson 8, Fahd Al-Mulla 9, Madeleine Duvic 3, Gen Sheng Wu 10, David T Dicker 2, Mala K Talekar 11, Bora Lim 3, Olivier Elemento 4, Wolfgang Oster 1, Joseph Bertino 7, Keith Flaherty 5,6, Michael L Wang 3, Gautam Borthakur 3, Michael Andreeff 3, Mark Stein 7, Wafik S El-Deiry 2,
PMCID: PMC8522842  PMID: 34676056

This article has been corrected: The COI statement has been updated. Please see the revised text below:

CONFLICTS OF INTEREST

W.S.E-D. is a co-founder and shareholder of Oncoceutics, Inc. W.S.E-D. is fully compliant with institutional disclosure requirements and conflict of interest rules. Dr. Michael Andreeff is also a shareholder of Oncoceutics, Inc. Some of the additional authors are employees or shareholders at Oncoceutics, Inc.

Original article: Oncotarget. 2016; 7:74380–74392. 74380-74392. https://doi.org/10.18632/oncotarget.11814


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES